Recent market situation of Onlykang and Weifang Jingxin Base

2022-10-22

       Recent market situation of Onlykang and Weifang Jingxin Base
Onlykang acquires cholesterol/VD series product enterprises from plants
Onlykang acquired 38.22% shares of Hunan Kerui Biopharmaceutical Co., Ltd. in cash. In addition to having held 23.48% of the shares of Kerui Bio before, Onlykang will acquire 61.70% of the shares of Kerui Bio in total and directly control Kerui Bio. According to the plan of Kerui Bio, the existing business of Kerui Bio will gradually change to the API business meeting the GMP standard, which will become the basis of the company's characteristic preparation business, for example, cholesterol will become the key auxiliary material of small molecule liposome drugs and nucleic acid drugs; Steramine APIs, cholic acid APIs, and ossifying alcohol APIs from vitamin D3 derivatives can all be developed into preparations.
Jingxin Weifang Base is expected to start trial production next year
Jingxin Pharmaceutical disclosed the information announcement of research activities. The new API base in Weifang, Shandong is under construction as planned. It is expected that some production facilities can be trial produced next year, which will ease the bottleneck of the company's API production capacity, and further optimize the company's API sector layout.

According to relevant laws and regulations, after review, the state has approved 10 kinds of veterinary drugs declared by 19 units including Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. as new veterinary drugs, issued the Registration Certificate of New Veterinary Drugs, issued product process procedures, quality standards, instructions and labels, and implemented them from the date of release. Approve the change registration of two kinds of veterinary drug products, including neomycin sulfate, declared by 3 units including Shandong Qifa Pharmaceutical Co., Ltd., and implement it from the date of release.

Situasi pasar baru-baru ini tentang Anglikang dan Pangkalan Weifang Jingxin

 

Anglikang mengakuisisi perusahaan produk Cholesterol/seri VD yang diturunkan dari tumbuhan:

Anglikang mengakuisisi 38,22% saham Hunan Kerey Pharmaceutical Co., Ltd. secara tunai. Selain sebelumnya memiliki 23,48% Kerey Pharma, Anglikang akan mengakuisisi total 61,70% Kerey Pharma dan langsung memegang Kerey Pharma. Sesuai rencana Kerey Pharma, bisnisnya sudah ada secara bertahap akan berubah menjadi bisnis API yang memenuhi standar GMP, yang akan menjadi fondasi bisnis persiapan khusus perusahaan, misalnya kolesterol akan menjadi obat liposom molekul kecil, asam nukleat Eksipien utama obat-obatan; API amina steroid, API asam kolat, dan produk turunan vitamin D3, API kalsidol, semuanya dapat dikembangkan menjadi sediaan.

 

Pangkalan Jingxin Weifang diharapkan untuk memulai produksi percobaan tahun depan：

Jingxin Pharmaceutical mengungkapkan pengumuman informasi kegiatan penelitian, pangkalan API yang baru dibangun di Shandong Weifang sedang dibangun sesuai rencana, dan diharapkan beberapa fasilitas produksi akan dapat menguji coba produksi tahun depan, yang akan mengurangi kemacetan produksi perusahaan API dan lebih mengoptimalkan tata letak segmen API perusahaan.

Menurut undang-undang dan peraturan terkait, setelah ditinjau, negara bagian telah menyetujui 10 produk obat hewan yang dinyatakan oleh 19 unit termasuk Harbin Pharmaceutical Group Bio-vaccine Co., Ltd. sebagai obat hewan baru, mengeluarkan "Sertifikat Pendaftaran Obat Hewan Baru", dan mengeluarkan peraturan proses produk, standar kualitas, instruksi dan Label, berlaku sejak tanggal publikasi. Menyetujui perubahan registrasi 2 produk obat hewan seperti neomycin sulfate yang dideklarasikan oleh 3 unit termasuk Shandong Qifa Pharmaceutical Industry Co., Ltd., yang akan dilaksanakan sejak tanggal rilis.